Stockreport

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Rapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis [Read more]